FDSA+ Multi-frequency Bioelectrical Impedance Analyser
Maltron’s FDSA+ BIA technology allows clinicians to monitor changes easily and accurately without the need of complex clinical techniques and optimize discharge time and decrease long-term complications.
Hypervolemic Euvolemic and Hypovolemic state
Intracellular & Extracellular Fluid
Body Fat
Muscle & Nutrition management
Accurate tracking of changes
Maltron Bioelectrical Impedance Analysis (BIA) is a simple, low-cost, non-invasive and non-intrusive method for the assessment of Body Water. The Total body Water (TBW) is divided into Intracellular (ICW) and Extracellular ECW) water. Fat Free Mass (FFM) is also assessed using Maltron BIA due to fact that total body water (TBW) makes up the most part of FFM.
Overhydration and dehydration in clinical children is a major cause of mortality. Assessments with Bioscan of Dehydration, Overhydration, Fat Free Mass Hydration (FFMH), Extracellular (ECW) and Intracellular Water (ICW) can assist effective fluid resuscitation and acheive optimal fluid balance.
BioScan 920-II-P the first real-time bedside, easy to use analyser for evaluating children. Assessment can provide healthcare professionals with an objective measure of patient’s targets for interventions which could improve perioperative experiences and postoperative outcomes.
Regular measurements of Total body water (TBW) Extracellular (ECW) and Intracellular Water (ICW) volume should be performed special after aggressive intravenous fluid therapy in Malnutrition, Sepsis, and Trauma infants. Maltron BioScan provides accurate bedside measurement of changes in body fluid compartments.
Estimating optimal Dry weight in children is important but difficult to establish with only clinical criteria. The goal in the treatment of dialysis is to achieve and maintain a euvolemic state. Currently euvolemic and “Dry weight” assessments are performed on a trial and error basis. Direct measurement with BioScan of Dry Weight, Excess water, TBW and ECW can provide qualitative information for assessing volume status.
Body composition assessment is an important indicator which should be assessed regularly in diabetic patients. Many complications can eventually develop in diabetes such as loss of Fats, Muscle Mass and Bone Minerals may eventually cause Osteoporosis. Therefore monitoring FM, Bone Density, FFM / Muscle Mass and GFR is very important.
Group of disorders such as diabetes and overactive thyroid glands which affect the metabolism of fat, carbohydrate, protein and minerals which in turn results in weight loss changing body composition. Body composition is an important indicator which should be assessed regularly with BioScan 920 to help with weight management programs.
Intracellular and extracellular volumes together with Total Body Water parameters enables clinicians to gain a better understanding of their patient's fluids status.
BioScan touch i8 NANO helps identify expected fluid and electrolyte shifts and renal function status.
Individually calibrated target ranges enables BioScan touch i8 NANO to guide clinicians tracking patient's fluid levels more precisely.
Maltron BioScan touch i8 NANO is a relatively inexpensive non-invasive, portable, easy to use method of assessment, which can be performed on any subject both in the field or clinical setting.
Published Clinical ResearchMaltron’s passion for pioneering and innovating technologies has lead Maltron to provide clinicians state of art tools for patient care. This has been independently evaluated and verified by clinical researchers.
T. Maehara, I. Novak, R. K. H. Wyse and
M. J. Elliot
The Hospital for Sick Children, Great Ormond Street, London, UK
Shime N, Ashida H, Chihara E, Kageyama K, Katoh Y, Yamagishi M, Tanaka Y.
Department of Anesthesiology and Intensive Care, Kyoto Prefectural University of Medicine, Japan
Margutti AV, Bustamante CR, Sanches M, Padilha M, Beraldo RA, Monteiro JP, Camelo JS Jr.
Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil
The parameters measured by the BioScan touch i8 NANO provide assessment of clinical and nutritional status helping detect abnormal conditions.
Critically ill children are at high risk of underfeeding and AKI, which may lead to further nutritional deficiencies.
As fluid administration is a real therapeutic challenge. Rather than reduce the patients care to a simple protocol, Maltron offers clinicians a quick and easy assessment tool to identify and consider the complete and often complex picture of patient’s status.
In critically ill patients fluid balance and weight can be influenced by several factors unrelated to body water, especially in the case of capillary leakage, digestive losses, fever or use of diuretics and ultrafiltration.
As a result of these changes the hydration status and water content cannot be assessed clinically. Maltron BioScan touch i8 NANO offers bedside monitoring to assess fluid status in critically-ill patients.
Despite many advances in diagnosis and treatment Kidney failure in Infants and Children still remains challenging.
To ensure normal growth Body Composition Assessment in Infants can provide more information about the nutritional status than the simple measurements of body length or weight. Accurate assessment to estimate dry weight can help improve fluid status of renal patients.
Malnutrition is unfortunately still common and is a key contributor to both global childhood morbidity and mortality
Seriously ill but compensating children will have signs of either shock or respiratory distress and yet still have a comparatively normal appearance and level of consciousness.
Children hospitalized for acute decompensated heart failure, are commonly known to have worsening renal function. They are associated with prolonged hospitalization and increased mortality or even requiring mechanical circulatory assistance.
After surgery, fluid accumulation changes and BioScan touch i8 NANO can assess these fluctuations.
The results of BioScan touch i8 NANO provide non-invasive accurate measurement and a follow-up can be undertaken in a wide range of cardiac clinical situations.
Malnourished children are a special category of patients who do not tolerate aggressive fluid resuscitation, as they are at greater risk of congestive heart failure from over-hydration. Septic shock can be difficult to recognize and treat in these patients. Malnourished children require slow IV rehydration with careful and regular observation.
Early diagnosis of fluid status in sepsis patients can help identify high-risk patients avoiding complications. Correct fluid status can be performed in Sepsis - ICU patients.
Every cancer is different and this is especially true for Neonates/Pediatrics. BioScan touch i8 NANO assessment of Muscle Mass can help identify high-risk Cancer patients. In the field of Oncology Maltron has established BioMarker base lines in order to predict patient outcome.
The treatment of chemotherapy dosages is presently based on Body Mass Index. By assessing Muscle Mass and adjusting Chemotherapy dosage long term effects could be reduced and improve patient outcomes.
Neonates/Pediatrics assessment of Malnutrition Index by the BioScan touch i8 NANO ensure age related development and maturity are met. Parameters available from the BioScan touch i8 NANO can help guide clinicians to better understand and provide relevant treatment which meets each patient's needs.
Helping babies achieve a healthy weight — free to reach their potential as adults
Performing detailed analysis of body composition and fluid status can help reduce the worsening conditions in critically ill Neonatal/Paediatrics.
The extensive range of each parameters measured by the Bioscan meets the comprehensive needs of each baby. The instantaneous assessment of fluid composition of the individual (including fluid status in the different bodily compartments) means Neonatologists/Paediatricians can identify patients in need of special attention.
Readily available parameters such as ICW and ECW Volume provides an exceptional diagnostic tool in identifying fluid, hydration and nutritional status.
Due to unique physiological and development needs, the treatment of Neonatal, Pediatric, Premature and ill new born babies is challenging. 
BioScan touch i8 NANO is World's first analyser to accurately identify infants at risk as young as 23 weeks gestational age.
Monitoring changes in hydration, loss of muscle mass and identifying malnutrition can aid clinicians to
perform
effectively and efficiently complex functions.
The specially designed proprietary algorithms allow BioScan touch i8 NANO to have moving target ranges which
change during the baby’s development period.
New integrated flagging features help keep track of patients in need of special attention and complying
with management protocols.
BioScan touch i8 NANO provides results in seconds rather than hours increasing effective screening, help decrease readmission rates and the duration of stay, which can help improve patient safety and expedite decision making.
Maltron International Ltd, 20 Sirdar Road, Rayleigh, Essex SS6 7XF. UK
Tel : +44 (0)1268 778251 Fax: +44 (0)1268 745176 - enquiries@maltronint.com
Copyright © 2015 - All Rights Reserved
